Psoriasis

Background and research focus

Background

Jo LW Lambert is full professor and academic dermatologist at the Dpt of Dermatology, of the Ghent University Hospital. Since 2006, she leads a psoriasis research line in the UGent Dermatology Research Unit (DRU), involving basic and translational research. The main aim is to understand psoriasis and its management from different angles: the work is categorized into 3 fields, PSO-Plus, Precision-PSO and Model-PSO.

It reflects translational and multidisciplinary research, from bedside to bench and vice versa, and has resulted in in more than 30 A1 publications (of over 180 in total) and 5 PhDs in the psoriasis-specific field since 2012.

Research focus

  • PSO-Plus: a specialized and multidisciplinary consultation format for psoriasis, based on a evidence-based medicine checklist to enable informed treatment decisions. The consultation PsoPlus receives 1200 psoriasis patients per year and acts as the reference center for psoriasis. PsoPlus allows concentrated patient recruitment as well as the extended database for research. Within this research line, we have defined a first treat-to-target concept for psoriasis, and we implement value-based healthcare (see Value-based healthcare in Chronic Dermatoses).
  • Precision-PSO: introduction of personalized and precision medicine in psoriasis management. Treatment optimization is studied by means of therapeutic drug monitoring, where the ideal dosage for each individual is determined. Moreover, to enable personalized healthcare, this research line includes biomarker studies to predict treatment response to specific drugs.
  • Model-PSO: This research line focuses on the development of in vitro and ex vivo models to mimic psoriasis-like inflammation in order to better understand its pathophysiology. Furthermore, this research line also includes the development and characterization of drug delivery systems for cutaneous conditions.

Members

Professors and Guest Professors

Jo Lambert, Reinhart Speeckaert

Postdoctoral researchers

Lynda Grine

PhD candidates

Tom Hillary (external), Lisa Schots, Rani Soenen

Technical staff

Martine De Mil, Els Van Maelsaecke

National and international collaborations

BIOLOPTIM

Implementing therapeutic drug monitoring of biologics for psoriasis and hidradenitis suppurativa 

  • Collaborator: Lab of Therapeutic and Diagnostic Antibodies, University of Leuven 

  • FWO: T001217N (TBM) (Amount : 980600 EUR) 

  • Aim: to develop algorithms for therapeutic drug monitoring (TDM) for biologicals used in the treatment of psoriasis (and hidradenitis suppurativa): adalimumab, secukinumab, ixekizumab, guselkumab, risankizumab and tildrakizumab. This includes measuring the drug’s concentration in serum or blood and how it benefits the patient (skin clearance). Hitherto, novel ELISA-based assays will be developed. The development of evidence-based methods and guidelines in TDM will lead to improved treatment options for the patient and better quality of life, more cost-effective use of biologics, and reduced costs for our healthcare system. 

BeNeBio

Dose reduction of the new generation biologics (interleukin 17 and interleukin 23 inhibitors) in psoriasis: A pragmatic, multicentre, randomized, controlled, non-inferiority study 

  • Collaborator: Radboud UMC, Nijmegen (the Netherlands) (Amount :1609340 EUR) 

  • BeNeFit: collaboration between KCE (BE) and ZonMW (NL) 

  • Aim: Patients treated with biologics against IL-17 or IL-23, with long-term stable low disease activity and a normal dose will be randomized into a dose-tapering arm (intervention) and a standard dose arm (control). Dose reduction by interval prolongation in 2 steps to a maximum decrease of 50% of the original dose when disease activity (PASI) and quality of life index (DLQI) remain low.Open-label, multi-centric randomised study; patients are randomized (2:1) to dose reduction or continuation of usual care. Outcome is defined as Cumulative incidence of persistent flares (PASI> 5 for ≥ 3 months). If positive, this study allows to optimize use of expensive drugs such as biologics, by tapering doses to the individual's response in clinical practice.

Defended PhDs (last 5 years)